Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Peptides expected to return to legal compounding status include: BPC-157 - studied for tissue repair, gut healing, and inflammation reduction Thymosin Alpha-1 - an immune-modulating peptide used in infectious disease and oncology support TB-500 (Thymosin Beta-4) - studied for muscle repair, flexibility, and recovery CJC-1295 and Ipamorelin - growth hormone-releasing peptides supporting sleep, metabolism, and lean muscle AOD-9604 - a peptide fragment studied for fat metabolism Selank and Semax - neuropeptides studied for cognitive function and anxiety GHK-Cu - a copper peptide studied for wound healing and regeneration MOTS-C - a mitochondrial peptide studied for metabolic regulation Important: Category 1 reclassification is not the same as FDA approval
The peptide can't mobilize fat when insulin is telling your body to store energy
Experts Recommendations for Early Screening and Diagnosis We recommend an annual screening for patients at risk of PN, such as obesity, prediabetes, NASH, and macronutrient deficiency, including individuals diagnosed with established diabetes
Human clinical safety data for BPC-157 is very limited
This water is intended formultiple-dose use, with the bacteriostatic agent inhibiting the growth of bacteria, allowing the vial to be re-entered multiple times under aseptic conditions
